Turnstone teams up with Takeda in $900M deal to work on biotech's oncolytic drug

Takeda US facility
Takeda will gain an exclusive worldwide license to co-develop and co-commercialize Turnstone’s leading (but still early-stage) oncolytic candidate RIVAL-01. (Takeda)

Fierce 15 winner Turnstone Biologics has penned a near $1 billion biobucks deal with biotech’s best friend, Takeda.

The pact, which has a substantial $120 million upfront in cash, sees Takeda gain an exclusive worldwide license to co-develop and co-commercialize Turnstone’s leading (but still early-stage) oncolytic candidate RIVAL-01. Turnstone also stands to receive up to $900 million in milestone payments.

Under the deal, global costs and profits will be shared 50-50, and the pair will also work together on other meds out of Turnstone’s so-called vaccinia virus platform.

Featured Webinar

How to Streamline Your Clinical Research Organization's Processes End to End

Learn how implementing one platform leads to data consistency and ultimately facilitate faster clinical trials while reducing overall trial costs, leave behind spreadsheets and home-grown tools for a predictable trial and the ability to forecast unit delivery resulting in the optics you need to ensure a successful trial, and hear experts share industry trends of what is affecting the Clinical Research Organization industry today.

Takeda also has the right to license certain meds from the collab, with Turnstone retaining ownership of the others to advance independently.

“Our collaboration with Takeda will combine our exciting viral immunotherapy platform with Takeda’s deep immuno-oncology research development expertise and proprietary technologies to discover and advance new medicines that have the potential to address critical gaps in the treatment of cancer that exist today,” said Sammy Farah, Ph.D., CEO and president of Turnstone Biologics.

“Importantly, this partnership allows us to co-develop and co-commercialize RIVAL-01 together with Takeda, enabling us to broaden our internal capabilities and expand our viral immunotherapy pipeline, while retaining our ability to independently develop other candidates based on this technology.”

RELATED: Turnstone Biologics nabs Bristol-Myers R&D executive as new research chief

RIVAL-01 works by encoding transgenes for Flt3 ligand, anti-CTLA-4 antibody and IL-12 cytokine. The transgenes are designed to be expressed when the vaccinia virus enters and replicates in cancer cells throughout the body.

Mike Burgess, Ph.D., president of R&D at Turnstone Biologics, explained that this drug is set up to deliver three “powerful immune modulating agents to primary and metastatic tumor sites and limit their expression to the local tumor environment, reducing the potential for systemic toxicity.”

He added that this has the “potential to drive immune activity in the tumor that is not otherwise achievable.”

This builds on Turnstone’s pact with AbbVie, which focuses on selected MG1 Maraba programs, and a collab and licensing agreement with the La Jolla Institute for Allergy and Immunology to develop new, neoantigen-based cancer immunotherapies.

Editor's note: This story was updated to include the financial breakdown of the deal.

Suggested Articles

MyoKardia wasn’t looking for a buyout when it started discussing potential partnerships with Bristol Myers Squibb last year.

Stanford University and its school of medicine have launched plans to survey the population of greater San Francisco for COVID-19.

Thermo Fisher's third-quarter revenue topped $8.52 billion, a 36% increase over the $6.27 billion raised during the same period in 2019.